Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. (SNY)

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,963,400
  • Shares Outstanding, K 2,504,140
  • Annual Sales, $ 42,147 M
  • Annual Income, $ 3,256 M
  • 60-Month Beta 0.51
  • Price/Sales 2.89
  • Price/Cash Flow 6.94
  • Price/Book 1.65
Trade SNY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.76
  • Number of Estimates 2
  • High Estimate 0.80
  • Low Estimate 0.72
  • Prior Year 0.74
  • Growth Rate Est. (year over year) +2.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.76 +1.21%
on 10/30/20
51.67 -12.33%
on 10/14/20
-4.87 (-9.71%)
since 09/30/20
3-Month
44.76 +1.21%
on 10/30/20
53.38 -15.13%
on 08/03/20
-7.20 (-13.71%)
since 07/30/20
52-Week
37.62 +20.41%
on 03/23/20
55.00 -17.64%
on 07/16/20
-2.16 (-4.55%)
since 10/30/19

Most Recent Stories

More News
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

JNJ : 137.11 (-0.06%)
SNY : 45.30 (-0.46%)
AZN : 50.16 (-1.78%)
PFE : 35.48 (+0.57%)
MRK : 75.21 (-0.90%)
LLY : 130.46 (-1.58%)
NVS : 78.08 (+0.01%)
Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

NVO : 63.89 (-3.68%)
SNY : 45.30 (-0.46%)
AZN : 50.16 (-1.78%)
LLY : 130.46 (-1.58%)
What's in the Cards for Regeneron's (REGN) Q3 Earnings?

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.

REGN : 543.56 (-2.20%)
SNY : 45.30 (-0.46%)
GERN : 1.7400 (-4.40%)
RGNX : 28.76 (-1.91%)
Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised

Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.

REGN : 543.56 (-2.20%)
SNY : 45.30 (-0.46%)
GSK : 33.42 (-1.59%)
TBIO : 12.83 (-5.17%)
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?

During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

SNY : 45.30 (-0.46%)
ALNY : 122.97 (-0.28%)
VRTX : 208.36 (+0.65%)
NVAX : 80.71 (-7.90%)
Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

CAMBRIDGE, Mass. and NEW YORK and , /PRNewswire/ -- Sanofi and the Parkinson's Foundation today announced a new research collaboration to advance the availability of genetic testing and counseling...

SAN : 2.01 (+2.55%)
SNY : 45.30 (-0.46%)
The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT

The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT

AMT : 229.65 (-0.86%)
HD : 266.71 (-1.08%)
AMZN : 3,036.15 (-5.45%)
INTC : 44.28 (+0.39%)
SNY : 45.30 (-0.46%)
Top Stock Reports for Amazon, Home Depot & Sanofi

Top Stock Reports for Amazon, Home Depot & Sanofi

SNY : 45.30 (-0.46%)
SAP : 106.83 (-1.66%)
INTC : 44.28 (+0.39%)
HD : 266.71 (-1.08%)
AMZN : 3,036.15 (-5.45%)
AMT : 229.65 (-0.86%)
Are Investors Undervaluing Sanofi (SNY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

SNY : 45.30 (-0.46%)
SNY or NVO: Which Is the Better Value Stock Right Now?

SNY vs. NVO: Which Stock Is the Better Value Option?

SNY : 45.30 (-0.46%)
NVO : 63.89 (-3.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 45.98
1st Resistance Point 45.64
Last Price 45.30
1st Support Level 44.86
2nd Support Level 44.42

See More

52-Week High 55.00
Fibonacci 61.8% 48.36
Fibonacci 50% 46.31
Last Price 45.30
Fibonacci 38.2% 44.26
52-Week Low 37.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar